The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.

NEW YORK – Fulgent Genetics announced on Thursday that it has obtained the CE-IVDR mark for its germline next-generation sequencing service. The CE marking covers the firm's FulgentExome, an ...

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

NEW YORK – Abbott said Thursday that its second quarter Diagnostics sales fell 1 percent to $2.17 billion compared to $2.20 billion in the prior-year. On an organic basis, Abbott's worldwide ...

The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.

Premier Medical owner and CEO Kevin Murdock paid kickbacks for cancer genetic testing referrals, defrauding Georgia, Colorado, and South Carolina Medicaid, DOJ said.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

Last week, readers were most interested in a story about an extended collaboration between Personalis and Tempus to include colorectal cancer.